Core Viewpoint - There is a significant trend of foreign capital inflow into Chinese companies, as evidenced by multiple global emerging market funds increasing their positions in Chinese stocks, particularly in the pharmaceutical sector [1][3]. Fund Activity - Invesco Developing Markets Fund increased its holdings in Hengrui Medicine by 100%, with a total market value of HKD 1.86 million after the increase [3]. - JPM China A-Share Opportunities Fund raised its stake in Hengrui Medicine by 18.49% [6]. - Allianz China A Shares Fund also increased its position in Hengrui Medicine by 8.47% [8]. Market Insights - The fund manager of Invesco, Justin Leverenz, expressed optimism about the Chinese pharmaceutical industry, noting that China has transitioned from a follower to a leader in drug development over the past five years [4]. - The Chinese biotechnology sector is still in its early stages, with significant potential for growth as companies have yet to fully engage in value-creating activities such as late-stage global clinical development and commercialization [4]. Performance Metrics - As of the end of May, the Invesco fund had a total size of approximately USD 14.1 billion (CNY 1012.41 billion) [3]. - The Allianz fund had a total size of USD 2.3 billion [8]. - The JPM fund had a total size of USD 2.8 billion [7]. Foreign Investment Sentiment - Temasek, Singapore's state investment firm, reported a net asset value of USD 340 billion, reflecting an 11.6% year-on-year growth, and continues to view China positively for long-term prospects [13].

Group 1: ETF Performance and Liquidity - The biopharmaceutical vaccine ETF has a turnover rate of 1.9% during trading, with a transaction volume of 4.8922 million yuan [3] - Over the past two weeks, the biopharmaceutical vaccine ETF has seen a scale increase of 8.7844 million yuan, ranking first among comparable funds [3] - As of July 10, the biopharmaceutical vaccine ETF has achieved a net value increase of 22.89% over the past year [3] - The ETF's highest monthly return since inception is 26.27%, with the longest consecutive monthly gain being 3 months and the longest gain percentage being 14.87% [3] - The average return during the months of increase is 6.41% [3] Group 2: Index Valuation and Composition - The index tracked by the ETF, the CSI Vaccine and Biotechnology Index, is currently valued at a historical low, with a price-to-book ratio (PB) of 2.6 times, which is lower than 88.03% of the time over the past three years, indicating strong valuation attractiveness [3] - The CSI Vaccine and Biotechnology Index includes no more than 50 companies involved in vaccine research, production, and related biotechnology sectors, reflecting the overall performance of listed companies in this theme [3] Group 3: Major Stocks and Market Trends - As of June 30, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index include Zhifei Biological Products, Wantai Biological Pharmacy, Watson Bio, and others, collectively accounting for 48.14% of the index [4] - The top weighted stocks and their respective weights are: Zhifei Biological (10.06%), Wantai Biological (8.43%), Watson Bio (6.19%), and others [6] - On July 8, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, proposing 16 supportive policies [6] Group 4: International Market Opportunities - Institutions are focusing on the opportunities for Chinese vaccines in international markets under the "World Shared Market" concept, particularly in Belt and Road countries [7] - Chinese vaccines are expected to leverage cost advantages to expand into the pharmaceutical markets of Belt and Road countries, especially in light of supply chain risks faced by non-U.S. countries [7] - The vaccine market is sensitive to population variables, and Chinese companies have established production capacity and distribution channels in Belt and Road countries, laying a solid foundation for international expansion [7]

Group 1 - Invesco Developing Markets Fund increased its holdings in Jiangsu Hengrui Pharmaceuticals by 100% in May, with a total market value of HKD 185,661,247 [2][3] - The fund's total size is approximately USD 14.1 billion, equivalent to about CNY 101.24 billion [2] - The fund's top five holdings include TSMC, Tencent, Huazhu Group, Kotak Mahindra Bank, and Meituan, with reductions in Tencent and Meituan by 5.31% and 24.77% respectively [3] Group 2 - Justin Leverenz, the fund manager, expressed optimism about the Chinese pharmaceutical industry, noting China's transition to a leader in drug development [4] - China has established a significant position in the global clinical and commercial landscape for blood cancer treatment, with its share of biotech licensing transactions increasing from 4% in 2019-2020 to 12% in 2023-2024 [4] Group 3 - JPMorgan Asset Management increased its stake in Jiangsu Hengrui Pharmaceuticals by 18.49% in May [5] - Allianz Investment also raised its holdings in Jiangsu Hengrui Pharmaceuticals by 8.47% [7] Group 4 - Fidelity China Focus Fund and FSSA China Growth Fund have also shown interest in various Chinese companies, with Fidelity increasing its stake in Alibaba by 12.46% and in Trip.com by 9.41% [9][10] - Temasek Holdings reported a net asset value of USD 340 billion, with a focus on long-term prospects in China, which represents 18% of its portfolio [11]

Group 1: Policy and Regulatory Updates - The National Healthcare Security Administration released the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with guidelines for commercial health insurance innovative drug catalog adjustments and negotiation rules for drug renewals [1] - The National Medical Products Administration held a national drug business supervision meeting, emphasizing the need for continued risk assessment and the fight against illegal activities in the pharmaceutical sector [2] Group 2: Company Developments - Novo Nordisk's 7.2mg semaglutide application for weight management has been accepted by the European Medicines Agency (EMA), based on positive results from Phase III STEP UP studies [4] - Ascentage Pharma's new drug lisatoclax has received conditional approval from the National Medical Products Administration for use in adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma [5] - Anke Bio announced a collaboration with Shengji Pharmaceutical for the exclusive agency of a recombinant human follicle-stimulating hormone-CTP fusion protein injection in mainland China and Hong Kong, Macau, and Taiwan [7] - Cornerstone Pharmaceuticals plans to place 100 million shares at a price of HKD 4.72 per share, aiming to raise a total of HKD 472 million as part of its financing plan [8] Group 3: Financial Performance - WuXi AppTec expects to achieve approximately CNY 20.799 billion in revenue for the first half of 2025, a year-on-year increase of about 20.64%, with adjusted net profit expected to be around CNY 6.315 billion, reflecting a growth of approximately 44.43% [10] - ST Sihuan anticipates a half-year revenue of CNY 180 million to CNY 190 million, representing a growth of 70.12% to 79.57%, but expects a loss of CNY 9 million to CNY 13 million [12] Group 4: Industry Collaborations - Baiao Biotechnology and BeiGene have reached a global licensing agreement for antibody molecules, which includes upfront payments and milestone payments based on development and commercialization [14]

Investment Rating - The report maintains a "Positive" investment rating for the healthcare industry [9]. Core Insights - Chinese pharmaceutical companies are increasingly enhancing their original research capabilities, leading to a surge in high-quality innovative products gaining international recognition. This trend is facilitating the acceleration of domestic innovative drugs entering global markets through two primary pathways: "building ships" and "borrowing ships" [2][6]. - The total value of license-out transactions from China reached over $43 billion in 2024, accounting for nearly 20% of the global total, indicating a significant shift in the global pharmaceutical landscape as Chinese innovative drugs gain traction [6][17]. Summary by Sections Innovative Drug Globalization - Chinese innovative drug companies are transitioning from "following overseas" to "independent innovation," with a notable increase in original research capabilities. The number of Chinese companies participating in major international conferences like AACR and ASCO has reached historical highs, with 126 companies presenting nearly 300 new drug research results at the 2025 AACR conference [17][18]. - The number of original innovative drugs approved in China has increased from 11 in 2015 to 92 in 2024, with the proportion of globally developed first-in-class (FIC) drugs rising from 9% to 24% during the same period [21][22]. "Building Ships" and "Borrowing Ships" Models - "Building ships" refers to domestic companies independently conducting overseas clinical trials and obtaining market approvals. Notable examples include BeiGene's BTK inhibitor, which achieved over $2.6 billion in global sales, and Legend Biotech's CAR-T therapy, which reached $963 million in global sales in 2024 [25][26]. - "Borrowing ships" involves leveraging partnerships for international development and commercialization. The total value of license-out transactions in the Chinese innovative drug sector reached $51.9 billion in 2024, with over 50 transactions reported in the first half of 2025, totaling $48.4 billion [27][28]. Investment Perspective - The report emphasizes that the ongoing transformation in the healthcare sector, driven by innovative drug globalization, presents significant investment opportunities. Companies with strong cash flow, innovative capabilities, and established research platforms are particularly well-positioned for growth [43].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1]. Group 1: Fund Performance - As of July 9, 2024, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 1.08% and a trading volume of 2.352 billion yuan [1]. - The fund's share volume increased by 419.87% from 3.95 million shares at the end of 2023 to 20.55 million shares by July 8, 2024 [1]. - The fund's size grew by 749.27%, from 378 million yuan at the end of 2023 to 3.209 billion yuan by July 8, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the cumulative trading amount for the ETF reached 42.082 billion yuan, with an average daily trading amount of 2.104 billion yuan [1]. - Since the beginning of the year, the ETF has recorded a total trading amount of 100.143 billion yuan over 124 trading days, averaging 808 million yuan per day [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF since its inception on January 3, 2024, achieving a return of 56.11% during the management period [1]. Group 4: Top Holdings - The ETF's top holdings include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others, indicating a focus on leading companies in the innovative drug sector [2]. - The fund's holdings are diversified across several key players in the biotechnology and pharmaceutical industries, with significant positions in companies like China Biologic Products and CSPC Pharmaceutical Group [2].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The CDK4 inhibitor BGB-43395 is progressing well and is expected to enter the registration clinical stage within the next 6-12 months, potentially becoming the second CDK4 inhibitor to do so globally [1][12]. - BGB-43395 demonstrates superior selectivity and efficacy compared to existing CDK4/6 inhibitors, with a significantly lower IC₅₀ of 126 nM, outperforming Pfizer's PF-07220060 by 4.3 times [2][17]. - The overall response rate for BGB-43395 is expected to improve with extended follow-up time, as historical data suggests that response rates for CDK4/6 inhibitors increase over time [3][28]. Financial Projections - Projected revenues for 2025-2027 are estimated at 375.17 billion, 450.24 billion, and 540.34 billion CNY, respectively [4]. - Expected net profits for the same period are projected to be 7.03 billion, 40.10 billion, and 67.44 billion CNY [4]. - The company anticipates a significant revenue growth rate of 82.13% in 2023, followed by 56.19% in 2024, and a gradual decline to 20.01% by 2026 and 2027 [5][40]. Clinical Development - BGB-43395 is currently involved in three Phase I clinical trials, focusing on monotherapy and combination therapies for HR+/HER2- breast cancer [1][12]. - The drug has shown promising pharmacokinetic and pharmacodynamic profiles, with rapid absorption and a half-life of approximately 13 hours [21][19]. - Initial clinical data indicates a favorable tumor response rate, with a stable disease plus partial response rate of 67% to 83% across different dosing groups [3][31]. Market Context - The global market for CDK4/6 inhibitors is projected to exceed 18 billion USD, with a 17% year-over-year growth expected in 2024 [16]. - BGB-43395's high selectivity minimizes the risk of toxicity associated with CDK6 inhibition, positioning it favorably against competitors [16][2].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年7月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | | 0.0001 USD | | 950,000 | | 2. 股份分類 | 其他分類 (請註明) | 股份類別 | 其他類別 (請註明) | | ...

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.44% on July 7, with a trading volume of 1.402 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 4, 2024, the fund's latest share count was 1.995 billion shares, with a total size of 3.203 billion yuan, reflecting a 404.69% increase in shares and a 747.72% increase in size year-to-date [1] Group 2 - The fund's liquidity showed a cumulative trading amount of 44.415 billion yuan over the last 20 trading days, with an average daily trading amount of 2.221 billion yuan [1] - Year-to-date, the cumulative trading amount reached 96.310 billion yuan over 122 trading days, with an average daily trading amount of 789 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 60.51% during the tenure [1] Group 3 - The top holdings of the Hong Kong Innovative Drug ETF include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others [2] - The fund's holdings are diversified across various companies in the innovative drug sector, with significant investments in both domestic and international firms [2]

Group 1 - The report highlights that innovative drugs are leading the pharmaceutical sector's market trends, with valuations expected to continue recovering [3][7][10] - The trend of innovative drugs going overseas is accelerating, which is likely to sustain the main market momentum [3][28] - The report indicates that the overall performance of the pharmaceutical sector faced pressure in Q1 2025, with a year-on-year revenue decline of 4.34% and a net profit drop of 8.87% [4][5] Group 2 - The report notes that the commercialization of domestic biotech innovative drug companies is entering a stable phase, with a significant revenue increase of 36% year-on-year in 2024, reaching 92.43 billion yuan [29][57] - It is projected that the domestic market for innovative drugs could reach 446 billion yuan by 2030, assuming a compound annual growth rate of 30% over the next six years [57][61] - The report emphasizes that the existing overseas licensing deals could yield a sales share of approximately 14.5 billion USD, based on conservative estimates of project success [61][62] Group 3 - The report suggests that there are opportunities for gradual recovery in various sub-sectors, including CXO, traditional Chinese medicine, and retail pharmacies, as operational improvements are expected [3][28] - The report identifies a significant increase in the holdings of innovative drug stocks by public funds, with a notable rise in the proportion of biotech innovative drug holdings [14][24] - The report outlines that the innovative drug sector is expected to benefit from breakthroughs in medical technology, including surgical robots and AI in healthcare [3][4][28]